Rovi receives offers for potential sale of €2B-plus CDMO group
MADRID, June 26 (Reuters) - Rovi (ROVI.MC), opens new tab has received non-binding offers for its third-party manufacturing business, the Spanish pharmaceuticals firm said on Wednesday, without disclosing the names of the bidders.
Rovi wins FDA nod to make Moderna’s COVID shot at Spanish plant
Rovi's Biologic Okedi (Resperidone) Receives Approval in Europe
CAMBRIDGE, MA and MADRID, SPAIN / ACCESSWIRE / February 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI's facilities, located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.
MADRID (Reuters) - Spain’s Rovi has agreed a 10-year extension to its deal with Moderna to manufacture future drugs developed with the mRNA technology used for the U.S. company’s coronavirus vaccine.
Moderna's contaminated doses contained metallic particles: report; China's Zhifei reports late-stage vaccine trail win. And more.
The contaminant found in Moderna COVID-19 vaccine vials in Japan is metallic particles, said public broadcasting outlet NHK. Moderna is investigating.